Age is the greatest risk factor for the development of Alzheimer disease (AD). Thus, understanding the genetic and pathological mechanisms that underlie the age-dependent development of AD neuropathological change is critical to our ability to monitor and target these pathways. Histone modifications and DNA methylation have been suggested as epigenetic factors mediating the influence of environmental factors on AD-related gene expression. Trimethylated histone H3K9 (H3K9me3) is one of the key histone modifications associated with decreased transcriptional activity and heterochromatin condensation. We have found that H3K9me3 levels are significantly altered in neurodegenerative disease. Here, we propose an integrated analysis of H3K9me3- chromatin immunoprecipitation (ChIP)-sequencing (ChIP-seq), DNA methylation, and mRNA quantification on brain tissue to determine how heterochromatin remodeling driven by H3K9me3 and DNA methylation is altered in aging and AD and to define the epigenome profiles linked to AD pathogenesis. Our preliminary data shows that two major pathways are genetically silenced in AD, including one in synaptic function (e.g. brain derived neurotrophic factor (BDNF) and synaptotagmin XII (SYT12)) and one involved in neuroinflammation (e.g. interleukin 1 (IL1), phospholipase A2 receptor 1 (PLA2R1), and latexin (LXN)). We propose a translational approach to systematically address AD neurodegeneration in one of the best characterized autopsy cohorts of aging on the DNA, RNA, and protein levels, with the goal of identifying novel epigenetic risk factors, biomarkers, and mechanisms that can be targeted for drug discovery. The Framingham Heart Study (FHS) collects extensive clinical and neuropsychological data, follows a community-based population throughout their lifetime, and collects the brain at death. Neuropathologically, subjects range from cognitively normal to demented and from pathologically normal to low AD neuropathological change to high AD change. Novel, digitized neuropsychological tests allow for the earliest detection of cognitive decline. Our long-term goal is to uncover the epigenetic and molecular mechanisms underlying the development of AD and of healthy aging. The immediate goal of this research project is to discover differences in the epigenetic silencing of synaptic and neuroinflammatory genes that predict AD pathology and cognitive impairment and that may serve as biomarkers and targets for therapy. This research will be critical for understanding how epigenetic changes are associated with aging and the development of AD, informing rational drug design, and for developing ways to assess risk in aging individuals.
We aim to link epigenetic and protein variation to the pathology of tau and A? in human subjects with a definitive pathological diagnosis and to the neuropsychological trajectory during life. Here we propose a cross-disciplinary approach that combines expertise and novel techniques in epigenetics, neuropathology, and cognitive testing to discover new pathogenic pathways for biomarker development and therapeutics.

Public Health Relevance

Histone modifications and DNA methylation are epigenetic factors that may mediate the influence of environmental factors on AD-related gene expression. The long-term goal of this research project is to uncover the epigenetic and molecular mechanisms underlying the development of AD and of healthy aging. The immediate goal is to discover differences in the epigenetic silencing of synaptic and neuroinflammatory genes that predict AD pathology and cognitive impairment and that may serve as biomarkers and targets for therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Multi-Year Funded Research Project Grant (RF1)
Project #
1RF1AG054156-01
Application #
9195889
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Wise, Bradley C
Project Start
2016-09-15
Project End
2021-06-30
Budget Start
2016-09-15
Budget End
2021-06-30
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Boston University
Department
Pathology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
Adams, Jason W; Alvarez, Victor E; Mez, Jesse et al. (2018) Lewy Body Pathology and Chronic Traumatic Encephalopathy Associated With Contact Sports. J Neuropathol Exp Neurol 77:757-768
Alosco, Michael L; Tripodis, Yorghos; Fritts, Nathan G et al. (2018) Cerebrospinal fluid tau, A?, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. Alzheimers Dement 14:1159-1170
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Cherry, Jonathan D; Mez, Jesse; Crary, John F et al. (2018) Variation in TMEM106B in chronic traumatic encephalopathy. Acta Neuropathol Commun 6:115
Morrison, Filomene G; Miller, Mark W; Wolf, Erika J et al. (2018) Reduced interleukin 1A gene expression in the dorsolateral prefrontal cortex of individuals with PTSD and depression. Neurosci Lett 692:204-209
Lee, Junghee; Nguyen, Phuong T; Shim, Hyun Soo et al. (2018) EWSR1, a multifunctional protein, regulates cellular function and aging via genetic and epigenetic pathways. Biochim Biophys Acta Mol Basis Dis :
Cherry, Jonathan D; Stein, Thor D; Tripodis, Yorghos et al. (2017) CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer's disease. PLoS One 12:e0185541
Cherry, Jonathan D; Tripodis, Yorghos; Alvarez, Victor E et al. (2016) Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. Acta Neuropathol Commun 4:112